Status: Not yet recruiting
Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.
This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the efficacy of this therapy.
Participants needed: 63
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Gritbio Medicine, Inc.Updated: Aug 14, 2026
Eligibility criteria
1 Age 18~70 years old; [+6]
1 Patients with spinal cord compression that has failed to resolve after surgery... [+10]